title: Pharmaceutical policy in China.
abstract: Contradictory goals plague China's pharmaceutical policy. The government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross-subsidize public hospitals. Yet the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients. The resulting system has distorted market incentives, increased consumers' costs, and financially rewarded inappropriate prescribing, thus undermining public health. Pharmaceuticals account for about half of total health spending in China, representing 43 percent of spending per inpatient episode and 51 percent of spending per outpatient visit. Yet some essential medicines are unavailable or of questionable quality.
authors.affiliation: Center for Health Management and Policy, Shandong University, in Jinan, People's Republic of China. karene@stanford.edu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Sun
authors.forename: Michael A
authors.initials: MA
authors.lastname: Santoro
authors.forename: Qingyue
authors.initials: Q
authors.lastname: Meng
authors.forename: Caitlin
authors.initials: C
authors.lastname: Liu
authors.forename: Karen
authors.initials: K
authors.lastname: Eggleston
mesh_terms: D002681:China; D003695:Delivery of Health Care / Q000458:organization & administration*; D016527:Drug Costs; D004345:Drug Industry / Q000458:organization & administration*; D004465:Economic Competition; D018166:Health Care Reform / Q000458:organization & administration*; D005102:Health Expenditures / Q000639:trends; D006291:Health Policy / Q000639:trends; D019458:Insurance Coverage / Q000639:trends